Back to Feed
ClinicalTrials.gov|Clinical Trial
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Abstract
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis Phase: PHASE2, PHASE3 Status: RECRUITING Conditions: Myasthenia Gravis; Generalized Myasthenia Gravis Interventions: Standard of Care Treatment; Standard lymphodepletion regimen; KYV-101
Keywords
Myasthenia GravisGeneralized Myasthenia Gravis